Cancer is an evolutionary disease, but does knowing a cancer’s evolutionary past help predict its future? Out today in @nature, we learnt the evolution of 2000 lymphoid cancers and found it was highly correlated with clinical outcomes! (1/7)
rdcu.be/eFrrc

Studying cancer evolution needs multi-region or single cell seq for phylogenetics, right? Amazingly (I think!) we found single-sample bulk methylation suffices, via analysis of "fluctuating methylation". In @nature.com today led by brilliant @calumgabbutt.bsky.social www.nature.com/articles/s41...

My main PhD project is now up on bioRxiv! If you’re interested in somatic evolution or machine learning for simulation-based inference, read on…

doi.org/10.1101/2025...
[1/15]

Had such a great time at #Londonomics2025 today - excellent talks and discussions - thank you to everyone who came along and shared their ideas with us.

🚨 PhD Position available in our lab 🚨 exploring the power of blood immune multi-omics to detect lung cancer years prior to clinical diagnosis in a unique cohort of >10,000 CT screened individuals.
✅ Wet & dry lab
✅ September 2025 enrolment
✅ UK tuition fees only

www.ucl.ac.uk/medical-scie...

📣📣 Another Londonomics Symposium! 📣📣

Last year was a great mix of computational biologists from biology, maths and computing backgrounds - I enjoyed it so much I joined the organising committee! Excited to meet people and talk cool science (including AlphaGenome, keynote from @avsecz.bsky.social!)

A day @ewanbirney.bsky.social posts a thread of "some musings" is a good day - I haven't (yet!) used MR in anger but this is a great checklist for how to do it properly.

Writing is thinking. A reminder on why scientists write, and why we should continue writing in the era of large-language models by Nature Review Bioengineering

@natureportfolio.nature.com
www.nature.com/articles/s44...
#AI #LLM 🧪

Great to see this work from @sandra-gl.bsky.social published yesterday, using mouse models to dig into the early stages of lung squamous cell carcinoma. Beautiful work on an important disease, congratulations to all involved!

Congratulation to the SUMMIT team on our publication in Lancet Oncology today: Low-dose CT for lung cancer screening in a high-risk population (SUMMIT): a prospective, longitudinal cohort study.
authors.elsevier.com/sd/article/S...

While progress has been made in treating #NSCLC, patients would further benefit from earlier detection & effective interception. Here, Spira and colleagues explore advances in identifying premalignant lesions, and devise approaches for stratification + interventions.

https://bit.ly/3QE86...

🚀 Our paper introducing ImmuneLENS, a new tool that measures T and B cell fractions from WGS data. This builds on our previous method, T cell ExTRECT, that used a signal from V(D)J recombination to measure T cells.

Out today in @naturegenet.bsky.social :
doi.org/10.1038/s41588-025-02086-5
🧵👇

Some musing this grey Saturday morning on one of my evergreen topics - the progress in rare disease diagnosis and treatments. TL;DR the world keeps making steady progress in diagnosing and then improving - sometimes to the point of a cure - rare disease. The rate of both will only increase.

This is brilliant science: an understanding of the basic biology of early cancer evolution through chromosomal instability, followed through to a new, cheap biomarker that can hopefully start to improve the lives of people with ulcerative colitis+low-grade dysplasia and catch more cancers early!